ROTHBLATT MARTINE A sold $5.1M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $540.18 ($533.79–$552.72, $5.13M total) across 13 trades on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale totals about $5.13M across 13 trades at prices roughly $533.79–$552.72, with holdings after the transaction of 40,513 shares; the presence of a 10b5-1 plan suggests reduced informational content.
Market read
Traders may monitor for additional insider activity, but the 10b5-1 framing makes this more of a sentiment datapoint than a fundamental catalyst.
What to watch
The article provides only the sale details; it does not state whether there were concurrent purchases, plan amendments, or changes in operating outlook that would strengthen the signal.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR) by its Chairperson & CEO, Martine Rothblatt.
Ticker impact
SEC Form 4 shows UTHR CEO/Chair Martine Rothblatt sold $5.13M of shares via an open-market sale under a 10b5-1 plan on 2026-06-18.
Likely limited, short-lived impact unless follow-on filings show accelerated selling or plan changes.
The filing is primary-source and quantifies sale size and price range, but it is explicitly pre-arranged under Rule 10b5-1, which typically dampens interpretive value versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals; traders may discount it.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderMartine A. Rothblatt
Chairperson & CEO who executed the open-market sale under a 10b5-1 plan.
